Marinus Pharma Finds $20M in 2nd Round

Xconomy Boston — 

Marinus Pharmaceuticals, a Branford, CT-based developer of drugs for neurological and psychiatric disorders, says it has closed a $20 million Series B round of financing from existing investors including Canaan Partners, Domain Associates, Foundation Medical Partners, and Sofinnova Ventures. The funding is intended to further develop the firm’s lead drug candidate, ganaxolone, as an additional treatment for refractory partial seizures and other conditions. Marinus says it has raised a total of $50 million in private financing.